Analysts/Institutional Investor Meet/Con. Call Updates

Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel 0124 492 1033 Fax 0124 492 1041 Emergency 105010 Email: secretarial@fortishealthcare.com Website : www.fortishealthcare.com August 11, 2026 FHL/SEC/2026-27 The National Stock Exchange of India BSE Limited Ltd. Scrip Symbol: FORTIS Scrip Code:532843 Sub: Transcript of Investors / Analyst’s meet under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Madam/Sir Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed transcript of Investors / Analysts’ meet held on August 7, 2026 to discuss the Company’s Un-audited Financial Results for the quarter ended on June 30, 2026 and same is available on the Website of the Company at below hyperlink: - https://www.fortishealthcare.com/investor/investor%20presentations%20&%20transcripts/earni ngs%20call%20transcript%20for%20the%20quarter%20ended%20june%202026 The date and time of occurrence of event is August 7, 2026 at 12.00 P.M This is for your information and record. Thanking you, Yours Sincerely, For Fortis Healthcare Limited Satyendra Chauhan Company Secretary & Compliance Officer ICSI Membership: A14783 Encl: a/a FORTIS HEALTHCARE LIMITED Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel : 0172-4692222, Fax : 0172-5096221, CIN : L85110PB1996PLC045933 “Fortis Healthcare Limited” Q1 FY27 Earnings Conference Call” August 07, 2026 MANAGEMENT: DR ASHUTOSH RAGHUVANSHI – MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER – FORTIS HEALTHCARE LIMITED MR. VIVEK GOYAL – CHIEF FINANCIAL OFFICER – FORTIS HEALTHCARE LIMITED MR. ANURAG KALRA – HEAD INVESTOR RELATIONS – FORTIS HEALTHCARE LIMITED MR. VIJENDER SINGH – MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER -- AGILUS DIAGNOSTICS MR. AKSHAY TIWARI -- CHIEF FINANCIAL OFFICER -- AGILUS DIAGNOSTICS Page 1 of 14 Fortis Healthcare Limited August 07, 2026 Moderator: Ladies and gentlemen, good day and welcome to the Fortis Healthcare Limited Q1 FY '27 earnings conference call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Anurag Kalra, Head of Investor Relations. Thank you, and over to you, sir. Anurag Kalra: Thank you, Alriac. Ladies and gentlemen, very good morning and good afternoon, and thank you for taking the time to join us on our quarter 1 FY '27 earnings call. The call is being chaired by our MD and CEO, Dr. Ashutosh Raghuvanshi. With him, we have our Chief Financial Officer, Mr. Vivek Goyal. From Agilus Diagnostics, we have the MD, Mr. Vijender Singh, and the Chief Financial Officer, Mr. Akshay Tiwari. We will start with some opening comments on the quarter 1 by Dr. Raghuvanshi, post which Mr. Vijender will take you through his thoughts on the Diagnostics business for the quarter, and then we can open the floor for question and answers. Over to Dr. Raghuvanshi. Ashutosh Raghuvanshi: Thank you, Anurag. Good morning, everyone, and thank you for taking time to join us on our Q1 financial year '27 earnings call today. At the outset, I would like to welcome Mr. Vijender Singh, who has recently joined us as MD and CEO of Agilus Diagnostics. I shall dive straight into the quarterly results and share my thoughts on the business performance and way forward. Building on the momentum of previous year, we have made a positive start to the financial year, delivering a steady Q1 performance across both our hospitals and diagnostic businesses. We reported consolidated revenue of INR 2,545 crores, a growth of 17.5% over Q1 of financial year '26. Noticeably, our hospital business revenues have grown by 19% to INR 2,187 crores while Q1 financial year '27 diagnostic business gross revenue has grown up by 10.2% to INR 407 crores versus the previous corresponding quarter. Our consolidated operating EBITDA pre-ESOP expenses increased by 15.8% to INR 568 crores, delivering a margin of 22.3% versus 22.6% in Q1 of financial year '26. The hospital business reported an operating EBITDA of INR 471 crores, which translates into a margin of 21.5% compared to 22.1% in Q1 of financial year '26. Performance of the quarter also includes recent acquisitions primarily related to the new hospital acquisitions in Punjab and Bengaluru and the leased facility in Delhi NCR. Excluding the impact of these facilities on a like-to-like basis, operating EBITDA margin in the quarter was similar to Q1 of financial year '26 at 22%. Page 2 of 14 Fortis Healthcare Limited August 07, 2026 The operating EBITDA margin of the Diagnostic business for the quarter improved to 23.9% from 23% in quarter 1 of financial year '26. Our consolidated reported profit after tax before exceptional items for the quarter increased by approximately 4% to INR 263 crores. On the balance sheet front, the company's net debt stands at INR 2,233 crores with a net debt- to-EBITDA ratio of 1.01x as of June 30, 2026, as against 0.92x on June 30, 2025. The increase in net debt compared to INR 1,869 crores as on 30th June '25 was primarily due to the acquisitions done last year. A bit of flavor on the hospital business. Our hospital occupancy in Q1 of financial year '27 remained steady at 69% compared to the corresponding period last year. However, the number of occupied beds increased by approximately 17% to 3,418 beds compared to 2,928 occupied beds in Q1 of financial year '26. After factoring in our recent acquisitions, the hospital business recorded an increase in ARPOB of 2.6%, reaching INR 2.71 crores per annum. Our key specialties such as renal sciences, neurosciences and orthopedics witnessed year-on- year revenue growth of 28%, 27% and 23%, respectively. In 14 of our facilities, we have reported operating EBITDA above 20% during the first quarter of financial year '27. These 14 facilities together contributed 70% to the hospital revenues. In comparison to financial year '26, we had 13 of our facilities operating EBITDA margin above 20%. Several of our key hospitals such as Jaipur, Noida, Faridabad, and Mulund witnessed margin expansion compared to the corresponding quarter of previous year and the trailing quarter. In addition, many of our key facilities such as Mulund and Faridabad and registered revenue growth in excess of 20% compared to the corresponding previous period. Our bed expansion plans continue to progress well. During the quarter, we added approximately 100 operational beds through brownfield expansion, primarily across our Noida, Amritsar, and Jalandhar facilities. We also recently entered into an O&M agreement for a 300-bedded greenfield multi-specialty hospital to be developed in Cuttack. This marks Fortis Healthcare's entry into Odisha, further expanding our presence in growth markets. Revenue from international business grew 13.3% compared to Q1 of financial year '26 to reach INR 174 crores. The contribution of international business revenue stood at approximately 8% in Q1 of financial year '27, on the similar lines as Q1 of financial year '26. We continue to invest in our medical infrastructure by expanding advanced robotic capabilities across our network, reinforcing our commitment to clinical excellence and technology during the quarter. We installed Da Vinci Xi soft tissue robots at Faridabad, Fortis Escorts Heart Institute, Okhla, and Ortho Robots at Jalandhar and Faridabad. Our Board has also approved installation of a proton facility at our flagship hospital in Gurgaon as well. Coming to the diagnostic business as part of our ongoing network expansion strategy, the total number of new customer touch points [Showing first 8,000 characters — download PDF for full document]